TD Cowen Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $354
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Ritu Baral maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $482 to $354.
TD Cowen analyst Ritu Baral maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $482 to $354.